Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kymera Therapeutics Inc
KYMR | US
73.21
USD1.92
2.69%
KYMR | US
About Kymera Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
03/06/2026
Close
73.21
Open
70.99
High
73.94
Low
69.48
Kymera Therapeutics Inc. a biopharmaceutical company focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program which is in Phase I clinical trial for the treatment of immunology-inflammation diseases including hidradenitis suppurativa atopic dermatitis macrophage activation syndrome general pustular psoriasis and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown Massachusetts.
View LessKYMR | US
Risk
48.4
Sharpe
1.07
Luna's Score
51/100
Recommendation
Hold
Luna says (KYMR | US)
What's Working
Strength based on increasing price with high volume
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
58.6%1 month
48.4%3 months
41.8%6 months
73.6%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.36
Debt to equity
0.13
Debt to assets
0.11
Ent. to EBITDA
-9.49
Ent. to rev.
28.97
PEG
-
Other Fundamentals
EBITDA
-176.97M
MarketCap
4.73B
MarketCap(USD)
4.73B
Div. yield
-
Op. margin
-198.54
Erngs. growth
-
Rev. growth
55.30
Ret. on equity
-28.18
Short ratio
19.78
Short perc.
15.23
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
13.44
Range1M
19.98
Range3M
20.66
Volumes: Market Activity
Rel. volume
1.67
Price X volume
62.00M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -9.49 | - | Cheaper |
| Ent. to Revenue | 28.97 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.36 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 41.77 | - | Lower Risk |
| Debt to Equity | 0.13 | -1.23 | Expensive |
| Debt to Assets | 0.11 | 0.25 | Cheaper |
| Market Cap | 4.73B | - | Market Leader |
